Data analysis

NeuroStar® Advanced Therapy Receives FDA Clearance as a First-Line Add-On Treatment for Adolescents with Depression

Retrieved on: 
Monday, March 25, 2024
Depression, Prevalence, Data analysis, MDD, COVID-19, Patient, Education, Ageing, Transcranial magnetic stimulation, TMS, DSM-IV codes, Quality of life, Adolescence, Safety, Marketing, STIM, FDA, Parent, Food, Pharmaceutical industry

NeuroStar is the first and only transcranial magnetic stimulation (TMS) treatment FDA-cleared for this age group, making it the fourth FDA-cleared indication for NeuroStar.

Key Points: 
  • NeuroStar is the first and only transcranial magnetic stimulation (TMS) treatment FDA-cleared for this age group, making it the fourth FDA-cleared indication for NeuroStar.
  • "The prevalence of depression in adolescents and young adults has been accelerating since the COVID-19 pandemic.
  • "NeuroStar’s TMS therapy now offers a promising first-line treatment for adolescents, backed by real-world data and impressive response rates consistent with response rates for adults.
  • This advancement has the potential to set a new treatment paradigm for how we address depression in our youth."

AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research

Retrieved on: 
Monday, March 25, 2024
Ovarian cancer, Gene, Clinical Cancer Research, Erasmus MC, Data analysis, Colorectal cancer, Progression-free survival, Patient, Neoplasm, Triple-negative breast cancer, Tumor microenvironment, Manuscript, Pancreatic cancer, Cancer, Doctor of Philosophy, MD, Epithelium, PD-L1, AIM, Liver, RNA, Vaccine

The manuscript titled “ Rintatolimod in Advanced Pancreatic Cancer enhances Anti-Tumor Immunity through Dendritic Cell-Mediated T Cell Responses ,” appears in the journal Clinical Cancer Research, one of oncology’s most prestigious journals.

Key Points: 
  • The manuscript titled “ Rintatolimod in Advanced Pancreatic Cancer enhances Anti-Tumor Immunity through Dendritic Cell-Mediated T Cell Responses ,” appears in the journal Clinical Cancer Research, one of oncology’s most prestigious journals.
  • Ampligen is a dsRNA product candidate that acts via the TLR-3 receptor present on several immune cells, epithelial cells and tumors.
  • Post-Ampligen, the increased peripheral abundance of BTLA+XCR1+ cDC1s and CD4+SELL+ T cells correlated with improved clinical outcomes.
  • Additionally, the changes in the tumor microenvironment we see in pancreatic cancer are similar to those we have seen in triple-negative breast cancer, ovarian cancer and colorectal cancer metastatic to the liver.

Bionomics Reports Results of the Full Dataset Analysis from ATTUNE Phase 2b Trial of BNC210 in Patients with Post-Traumatic Stress Disorder

Retrieved on: 
Thursday, March 21, 2024
Week, Selective serotonin reuptake inhibitor, Data analysis, Post-traumatic stress disorder, Central nervous system, Patient, CNS, BNC210, Safety, DSM-5, FDA, PTSD, Pharmaceutical industry

ADELAIDE, Australia and CAMBRIDGE, Mass., March 21, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced the release of the full dataset analysis from its Phase 2b ATTUNE trial in patients with post-traumatic stress disorder.

Key Points: 
  • In September 2023, Bionomics reported the topline results for the Phase 2b ATTUNE trial of BNC210 in patients with PTSD demonstrating that the trial met its primary endpoint and several secondary endpoints, and that BNC210 was generally well tolerated.
  • The full data analysis is detailed below and in an accompanying presentation of the results that is posted on the Company’s website .
  • “The full results of the ATTUNE Phase 2b trial further strengthen, the already compelling, topline results and position BNC210 as a potential highly differentiated treatment with rapid onset and durable efficacy that could improve outcomes for patients with PTSD.
  • Following the ATTUNE Phase 2b trial readout and based on a safety database of ~600 patients, BNC210 continues to demonstrate a non-sedating, non-habit forming, non-cognition impairing psychoactive profile.

MarketSpy Emerges as an Innovative Platform for Breaking Insights in Tech, Crypto, and Gaming!

Retrieved on: 
Wednesday, March 20, 2024
Education, Knowledge, Growth, Sport, Ecosystem, Data analysis

With a focus on technology, cryptocurrency, gaming, and beyond, MarketSpy is revolutionizing the way people stay informed and ahead of the curve.

Key Points: 
  • With a focus on technology, cryptocurrency, gaming, and beyond, MarketSpy is revolutionizing the way people stay informed and ahead of the curve.
  • With over two decades of experience, MarketSpy has become a trusted source for individuals and professionals seeking to navigate the complexities of the modern world.
  • "At MarketSpy, our mission is to empower our users with the knowledge and insights they need to succeed," said Lishan, the owner of MarketSpy.
  • With its innovative approach and commitment to delivering cutting-edge insights, MarketSpy is poised to revolutionize the way people stay informed and make informed decisions across various industries and interests.

Milvus 2.4 Unveils Game-Changing Features for Enhanced Vector Search

Retrieved on: 
Wednesday, March 20, 2024
Inverted index, ANN, Algorithm, GPU, Data analysis, BM25, Multi, Expression, Collection, NVIDIA, Metadata

A new feature of Milvus 2.4 is its Multi-vector support, offering an end-to-end infrastructure solution for multi-vector search and reranker functionalities.

Key Points: 
  • A new feature of Milvus 2.4 is its Multi-vector support, offering an end-to-end infrastructure solution for multi-vector search and reranker functionalities.
  • Milvus 2.4 introduces a Grouping Search operation to enhance resource efficiency and developer productivity by ensuring users receive relevant and meaningful search results.
  • Milvus 2.4 introduces sparse vector support, facilitating efficient ANN search over sparse embeddings generated by models like SPLADEv2 or statistical models like BM25.
  • This enhances the accuracy of text search using hybrid search methodologies, providing users with more nuanced and relevant search results.

Agital Upgrades Its Agital Impact Platform, Introducing Sophisticated New Reporting and Analytics Capabilities

Retrieved on: 
Tuesday, March 19, 2024
Contextual advertising, Advertising, Forecasting, Comparison, Media, Digital, Data analysis, Luigi, Impact, CLV, Customer lifetime value, MMM, Marketing, Visualize, Retail

Agital Impact offers a single view of performance across more than 25 channels and platforms and provides sophisticated capabilities to make future-proof decisions through forecasting and modeling.

Key Points: 
  • Agital Impact offers a single view of performance across more than 25 channels and platforms and provides sophisticated capabilities to make future-proof decisions through forecasting and modeling.
  • Agital Impact solves these challenges by going beyond performance tracking to deliver sophisticated modeling and holistic business insights.
  • Agital Impact offers out-of-the-box advanced analytics capabilities that help companies of all sizes - from SMBs to emerging enterprises and global brands - optimize business performance through accessible, easy-to-understand insights reporting.
  • Agital Impact also introduced Visualize, a cutting-edge application that integrates presentation capabilities into Agital Impact's sophisticated analytics suite, now comprising three different applications: Inform, Visualize, and Compare.

ClearlyRated Announces Its 2024 Best Staffing Firms for Women™ List

Retrieved on: 
Tuesday, March 19, 2024
Best, Data analysis, Dräxlmaier Group, Satisfaction (Benny Benassi song), Research, Female, Woman, Male, Women's History Month, Workforce, DEI

PORTLAND, Ore., March 19, 2024 (GLOBE NEWSWIRE) -- ClearlyRated®, the leading provider of client, talent, and employee satisfaction surveys and service quality research for staffing & recruiting agencies, announced the firms that have qualified for inclusion on the second annual Best Staffing Firms for Women™ list on ClearlyRated.com .

Key Points: 
  • PORTLAND, Ore., March 19, 2024 (GLOBE NEWSWIRE) -- ClearlyRated®, the leading provider of client, talent, and employee satisfaction surveys and service quality research for staffing & recruiting agencies, announced the firms that have qualified for inclusion on the second annual Best Staffing Firms for Women™ list on ClearlyRated.com .
  • "I'm excited to announce the firms that have earned the second annual Best Staffing Firms for Women designation," stated Eric Gregg, CEO of ClearlyRated.
  • Staffing and recruiting firms that conducted internal employee surveys with ClearlyRated are eligible to earn the Best of Staffing® award in the Employee Satisfaction category.
  • Some of the notable findings from ClearlyRated’s internal staffing employee data analysis include the following:
    Females comprise 68% of all internal positions at staffing firms, yet nearly two thirds of executives are male
    Employees at Best of Staffing winning firms were:
    Fewer than 0.2% of staffing firms in the United States and Canada qualified to earn the Best Staffing Firms for Women designation, making this a prestigious recognition for staffing firms seeking to hire and retain top internal talent.

Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer

Retrieved on: 
Monday, March 18, 2024
DAS, Retina, University, Moorfields Eye Hospital, Pathology, Oligonucleotide, Ranibizumab, Data analysis, Partnership, Business, Boehringer Ingelheim, DME, Patient, Pharming, Research, Royal College of Ophthalmologists, Cell biology, Diabetic retinopathy, C3, University College London, MBA, Eye, Johnson & Johnson, Janssen, Drug development, John Radcliffe Hospital, AMD, CLS, University of Oxford, Royal college, Geographic atrophy, Stargardt disease, DMI, Pharmaceutical industry

ALPHARETTA, Ga., March 18, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that Victor Chong, M.D., MBA was appointed Chief Medical Officer on March 14, 2024.

Key Points: 
  • ALPHARETTA, Ga., March 18, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that Victor Chong, M.D., MBA was appointed Chief Medical Officer on March 14, 2024.
  • George Lasezkay, Pharm.D., J.D., President and Chief Executive Officer of Clearside, commented, “Victor is a well-known and well-respected retinal clinician and scientist, who is a strategically focused and visionary leader.
  • We are delighted to have him join the Clearside team.
  • “With the upcoming ODYSSEY data and extensive partnership portfolio, this is an exciting time to join Clearside.

Anavex Life Sciences Initiates Placebo-Controlled U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia

Retrieved on: 
Monday, March 18, 2024
EEG, U.S. FDA, Schizophrenia, Deficit spending, Data analysis, Memory, Alzheimer's disease, Central nervous system, Part, Delusion, Patient, CNS, ERP, Biomarker, Doctor of Philosophy, Parkinson's disease, Quality of life, Personalized medicine, Life, Trial of the century, Positive, Rett syndrome, Hallucination, PANSS, Therapy, SIGMAR1, DSM-IV codes, FDA, Pharmaceutical industry

NEW YORK, March 18, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental, and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, Rett syndrome, schizophrenia, and other central nervous system (CNS) diseases, today announced that the first patient in its U.S. FDA cleared placebo-controlled Phase 2 clinical study of ANAVEX®3-71 for the treatment of schizophrenia has been screened ahead of schedule.

Key Points: 
  • “Initiating our Phase 2 trial of ANAVEX®3-71 in schizophrenia ahead of schedule is a testament to the hard work and dedication of our clinical study team,” stated Christopher U Missling, PhD, President and Chief Executive Officer of Anavex.
  • “Schizophrenia is a challenging disorder that can impair social and occupational functions and overall quality of life for the nearly 24 million people affected worldwide.
  • The placebo-controlled Phase 2, two-part, in-patient trial, ANAVEX®3-71-SZ-001 ( NCT06245213 ), will investigate the effects of ANAVEX®3-71 in patients with schizophrenia.
  • In addition to the electrophysiological biomarkers, Anavex is applying novel neuroinflammatory, metabolomic, and transcriptomic biomarkers at the intersection of schizophrenia pathophysiology and ANAVEX®3-71’s novel, dual mechanism of action.

ImpactMapper integrates with Trint to Expedite Impact Reporting and Analysis of Interviews and Reports

Retrieved on: 
Thursday, March 14, 2024
UX, CRM, AP, IKEA, Woman, Data analysis, Financial Times, Social justice, Salesforce, DLA, Malala Fund, Fluxx, Interview, Doctor of Philosophy, Life, Piper, Data collection, UNDP, API, UN Women, DLA Piper, BBC, UN

“ImpactMapper is the only impact reporting tool on the market that takes qualitative data seriously. This is incredibly important as groups all over the world are making critical social justice, equity, and environmental changes that affect rights, policies, and norms. The changes and impact they are making come to life when they are contextualized and deeper examples and stories of changes are shared. As such, we often recommend to the foundations and donors that we work with to move to oral reporting formats to better track this type of impact and to decrease the reporting burden on their partners. We also underscore the importance of qualitative data, such as interviews and focus groups, for landscaping, context, and outcome analysis. In this effort to move to trust-based reporting practices in philanthropy, transcription tools like Trint are often used. The integration with ImpactMapper strengthens trust-based reporting practices in philanthropy and gives a concrete set of tools to make this happen. The integration also supports ImpactMapper in opening up to other markets, such as journalists, companies, UX experts, and other users of Trint software that are interested in tagging their audio and video transcripts thematically, aggregating trends, and visualizing data trends across a set of stories, interviews or clients.” -- Alexandra Pittman, PhD, Founder and CEO, ImpactMapper  

Key Points: 
  • After users record an interview, focus group, or grantee reporting session in Trint, they can automatically import Trint transcripts into ImpactMapper for deeper analysis and visualization.
  • This real-time integration saves users valuable time, ensures they always have access to the newest reports and interviews and helps to ensure that transcripts are analyzed and used for impact reporting.
  • ImpactMapper has robust qualitative text analysis tools, in addition to financial and quantitative analysis and a survey tool, creating an all-in-one flexible data analysis, visualization, and impact reporting solution for users.
  • A set of equitable AI and autocoding tools is also being developed in 2024 to make impact reporting even more efficient through the ImpactMapper software.